CN101057885A - 一种治疗骨质疏松的中药组合物及其制剂和用途 - Google Patents
一种治疗骨质疏松的中药组合物及其制剂和用途 Download PDFInfo
- Publication number
- CN101057885A CN101057885A CN 200610076304 CN200610076304A CN101057885A CN 101057885 A CN101057885 A CN 101057885A CN 200610076304 CN200610076304 CN 200610076304 CN 200610076304 A CN200610076304 A CN 200610076304A CN 101057885 A CN101057885 A CN 101057885A
- Authority
- CN
- China
- Prior art keywords
- group
- fructus psoraleae
- chinese medicine
- total coumarins
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims description 46
- 239000003814 drug Substances 0.000 claims abstract description 67
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 155
- 235000001671 coumarin Nutrition 0.000 claims description 155
- 150000004775 coumarins Chemical class 0.000 claims description 155
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 70
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 35
- XDROKJSWHURZGO-UHFFFAOYSA-N angelicin Chemical compound C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 claims description 31
- 239000011347 resin Substances 0.000 claims description 30
- 229920005989 resin Polymers 0.000 claims description 30
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 claims description 24
- 239000012567 medical material Substances 0.000 claims description 22
- 239000012535 impurity Substances 0.000 claims description 18
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 14
- 230000001009 osteoporotic effect Effects 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- 238000001291 vacuum drying Methods 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000005325 percolation Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- -1 patch Substances 0.000 claims description 3
- 238000010926 purge Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000000470 constituent Substances 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 4
- 241001446509 Psoralea Species 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 81
- 239000011575 calcium Substances 0.000 description 31
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 30
- 229910052791 calcium Inorganic materials 0.000 description 30
- 241000700159 Rattus Species 0.000 description 29
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 28
- 229940062527 alendronate Drugs 0.000 description 28
- 230000037182 bone density Effects 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 24
- 229940088597 hormone Drugs 0.000 description 23
- 239000005556 hormone Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 20
- 238000011552 rat model Methods 0.000 description 19
- 210000000689 upper leg Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 17
- 239000011574 phosphorus Substances 0.000 description 17
- 229910052698 phosphorus Inorganic materials 0.000 description 17
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 16
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 102000055006 Calcitonin Human genes 0.000 description 12
- 108060001064 Calcitonin Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229960004015 calcitonin Drugs 0.000 description 12
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 11
- 241001484259 Lacuna Species 0.000 description 11
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 11
- 229960002591 hydroxyproline Drugs 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 11
- 102000004067 Osteocalcin Human genes 0.000 description 10
- 108090000573 Osteocalcin Proteins 0.000 description 10
- 210000004409 osteocyte Anatomy 0.000 description 10
- 210000004100 adrenal gland Anatomy 0.000 description 9
- 239000003513 alkali Substances 0.000 description 9
- 230000000630 rising effect Effects 0.000 description 9
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 8
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 8
- 230000001054 cortical effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 229960003604 testosterone Drugs 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 229960003624 creatine Drugs 0.000 description 7
- 239000006046 creatine Substances 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 230000002485 urinary effect Effects 0.000 description 7
- 239000009750 xian ling gu bao Substances 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 6
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 6
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000011572 manganese Substances 0.000 description 6
- 229910052748 manganese Inorganic materials 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 239000003463 adsorbent Substances 0.000 description 5
- 230000000274 adsorptive effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- QIMGSZURBOTPMW-UHFFFAOYSA-N 2-methoxy-5-(2,3,4-trimethoxyphenyl)cyclohepta-2,4,6-trien-1-one Chemical compound COC1=C(OC)C(OC)=CC=C1C1=CC=C(OC)C(=O)C=C1 QIMGSZURBOTPMW-UHFFFAOYSA-N 0.000 description 4
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 4
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000018678 bone mineralization Effects 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000013425 morphometry Methods 0.000 description 4
- 210000004417 patella Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108010048734 sclerotin Proteins 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 102000013563 Acid Phosphatase Human genes 0.000 description 3
- 108010051457 Acid Phosphatase Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000011785 micronutrient Substances 0.000 description 3
- 235000013369 micronutrients Nutrition 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- FGMPLJWBKKVCDB-BYPYZUCNSA-N (2s)-1-hydroxypyrrolidine-2-carboxylic acid Chemical compound ON1CCC[C@H]1C(O)=O FGMPLJWBKKVCDB-BYPYZUCNSA-N 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 244000241463 Cullen corylifolium Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
- 229960000452 diethylstilbestrol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000522215 Dipteryx odorata Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical group [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 229930009960 Isopsoralidin Natural products 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229930030856 Psoralidin Natural products 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- MPMBRWOOISTHJV-UHFFFAOYSA-N but-1-enylbenzene Chemical compound CCC=CC1=CC=CC=C1 MPMBRWOOISTHJV-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
化合物 | 中文名 | 英文名 |
12 | 补骨脂素异补骨脂素 | psoralenisopsoralen |
组别 | 剂量(mg/kg) | 动物数(n) | 股骨骨干(g/cm2) | 股骨近心端(g/cm2) | 股骨远心端(g/cm2) |
空白对照组模型对照组天可片组仙灵骨葆组补骨脂总香豆素 | --1.7650051020 | 10161613141517 | 0.24±0.020.16±0.02△△△0.18±0.04*0.19±0.05*0.18±0.040.19±0.05*0.20±0.04** | 0.25±0.020.18±0.02△△△0.21±0.04*0.20±0.05*0.20±0.04*0.20±0.04*0.22±0.04** | 0.24±0.030.15±0.01△△△0.18±0.03**0.19±0.05**0.17±0.040.19±0.05**0.19±0.04** |
组别 | 剂量(mg/kg) | 动物数(n) | 血钙(mmol/L) | 血磷(mmol/L) |
空白对照组模型对照组天可片组仙灵骨葆组补骨脂总香豆素 | --1.7650051020 | 10161613141517 | 2.34±0.261.81±0.23△△△2.02±0.18**2.00±0.25*2.00±0.25*2.05±0.30**2.16±0.24** | 1.42±0.412.12±0.68△△1.50±0.54**1.60±0.43*1.73±0.441.64±0.44*1.52±0.53** |
组别 | 剂量(mg/kg) | 动物数(n) | StrACP(U/mL) | ALP(U/L) |
空白对照组模型对照组天可片组仙灵骨葆组补骨脂总香豆素 | --1.7650051020 | 10161613141517 | 20.31±6.8031.82±9.87△△25.14±3.77*23.99±6.41*25.07±4.09*24.04±7.09*22.49±6.62** | 114.27±55.57309.56±66.32△△△219.62±82.02**233.78±51.89**264.62±39.98*238.57±38.86**189.98±33.76** |
组别 | 剂量(mg/kg) | 动物数(n) | 尿羟脯氨酸/尿肌酐(μg/mmol) |
空白对照组模型对照组天可片组仙灵骨葆组补骨脂总香豆素 | --1.7650051020 | 10161613141517 | 22.91±15.28101.21±65.92△△△47.47±56.83*36.73±18.55**53.79±31.50*45.33±23.84**38.23±21.47** |
组别 | 剂量(mg/kg) | 动物数(n) | 血清羟脯氨酸(μg/mgprot) |
空白对照组模型对照组天可片组仙灵骨葆组 | --1.76500 | 10161613 | 2.43±0.534.33±0.86△△△3.37±0.91**3.30±0.99** |
补骨脂总香豆素 | 51020 | 141517 | 3.61±0.80*3.51±0.67**3.30±0.95** |
组别 | 剂量mg/kg | 动物数(n) | 脾脏(%) | 肾脏(%) | 胸腺(%) | 肾上腺(%) |
空白对照组模型对照组天可片组仙灵骨葆组补骨脂总香豆素 | --1.7650051020 | 10161613141517 | 0.19±0.050.23±0.060.22±0.040.20±0.060.20±0.050.21±0.050.20±0.05 | 0.55±0.060.57±0.100.56±0.090.62±0.110.53±0.080.57±0.060.60±0.10 | 0.08±0.030.06±0.020.08±0.040.07±0.020.08±0.020.08±0.030.08±0.02 | 0.026±0.0040.019±0.006△△0.025±0.008*0.025±0.006*0.024±0.0080.025±0.008*0.026±0.009* |
组别 | 剂量(mg/kg) | 动物数(n) | 骨钙素(ng/ml) |
空白对照组模型对照组天可片组仙灵骨葆组补骨脂总香豆素 | --1.7650051020 | 10101010101010 | 3.83±2.101.71±0.45△△4.22±1.65***3.32±1.34**2.53±0.59**3.01±0.77***3.77±1.43*** |
组别 | 剂量(mg/kg) | 动物数(n) | 降钙素(pg/ml) |
空白对照组模型对照组天可片组仙灵骨葆组补骨脂总香豆素 | --1.7650051020 | 10101010101010 | 165.72±83.1637.20±12.60△△△148.49±86.6***110.42±65.65**88.03±41.14**105.83±39.98**157.90±88.80** |
组别 | 剂量(mg/kg) | 动物数(n) | 睾酮(ng/dl) |
空白对照组模型对照组天可片组仙灵骨葆组补骨脂总香豆素 | --1.7650051020 | 10101010101010 | 248.03±127.4710.00±7.26△△△232.88±154.01***137.92±127.34**30.58±26.23*53.36±36.81**186.14±103.69*** |
组别 | 剂量mg/kg | 动物数(n) | 钙(%) | 磷(%) | 镁mg/kg | 锌mg/kg | 锰mg/kg | 铜mg/kg |
空白对照组模型对照组天可片组仙灵骨葆组 | --1.76500 | 10161613 | 4.63±0.524.07±0.66△4.63±0.81*5.03± | 12.07±0.9311.30±2.3212.07±2.1111.50± | 4312.9±419.13879.9±957.04380.2±1020.84105.2± | 226.68±18.69225.35±28.68226.10±26.45207.11± | 6.94±0.656.29±0.44△△5.77±0.60**6.12± | 5.39±1.215.37±1.774.63±0.995.07± |
补骨脂总香豆素 | 51020 | 141517 | 0.52***4.41±0.704.63±0.50*4.59±0.76* | 1.1211.02±0.9911.30±0.7011.86±2.55 | 501.63763.7±361.34006.7±251.14135.9±1032.3 | 35.72241.35±28.09231.82±29.81246.27±23.57 | 0.575.63±0.43***6.04±0.435.88±0.68* | 0.785.50±0.445.35±0.895.43±0.64 |
组别 | 剂量mg/kg | 动物数(n) | TBV(%) | MTPT(um) | Nocy(%) | CBV(%) | MAR(um/天) | MOSW(um) |
空白对照组模型对照组天可片组仙灵骨葆组补骨脂总香豆素 | --1.76500510 | 101616131415 | 31.99±5.5620.03±4.20△△△26.68±5.65***25.82±6.05**23.63±5.32*23.74±4.01* | 100.58±11.5178.85±12.21△△△90.46±9.93***91.84±9.54**82.31±11.9887.13±8.45* | 4.28±0.452.84±0.80△△△3.92±0.64***4.50±0.57***3.27±0.754.10±1.36** | 2.67±0.631.09±0.31△△△1.61±0.48**1.62±0.57**1.58±0.68*1.71±0.79** | 1.78±0.291.40±0.30△△1.62±0.341.69±0.29*1.80±0.59*1.68±0.29* | 50.14±7.4643.11±4.20△△50.61±5.57***49.79±6.84**46.71±5.32*49.01±7.18** |
20 | 17 | 28.87±7.25*** | 89.59±9.87** | 4.25±0.96*** | 1.67±0.73** | 1.81±0.50* | 49.58±4.81*** |
组别 | 剂量(mg/kg) | 动物数(n) | 股骨骨干BMD(g/cm2) | 股骨头BMD(g/cm2) | 膝盖骨BMD(g/cm2) |
正常组模型组阳性组补骨脂总香豆 | --22.5μg/kg510 | 1517181718 | 0.32±0.010.28±0.01△△△0.31±0.01***0.30±0.01***0.29±0.01*** | 0.41±0.020.36±0.02△△△0.40±0.02***0.38±0.01**0.39±0.01*** | 0.35±0.010.31±0.01△△△0.33±0.01***0.32±0.01*0.33±0.01*** |
素 | 20 | 18 | 0.31±0.01*** | 0.40±0.02*** | 0.33±0.01*** |
组别 | 剂量(mg/kg) | 动物数(n) | 血钙(mmol/L) | 血磷(mmol/L) |
正常组模型组阳性组 | --22.5ug/kg | 151515 | 2.53±1.041.76±0.44△2.28±0.81* | 2.20±0.603.23±0.68△△△2.11±0.68*** |
补骨脂总香豆素 | 51020 | 151714 | 1.85±0.552.24±0.70*3.10±0.48*** | 2.60±0.49**2.35±0.68**1.88±0.29*** |
组别 | 剂量(mg/kg) | 动物数(n) | StrACP(U/ml) | ALP(U/L) |
正常组模型组阳性组补骨脂总香豆素 | --22.5ug/kg51020 | 151517161515 | 68.47±21.42117.12±25.69△△△77.70±30.01***95.22±47.77*93.05±23.94*71.42±16.85*** | 68.47±21.42120.96±38.45△△△79.03±33.52**93.84±33.63*93.24±22.22*67.30±12.99*** |
组别 | 剂量(mg/kg) | 动物数(n) | 骨钙素(ng/ml) | 降钙素(pg/ml) | 雌二醇(ng/dl) |
正常组模型组阳性组补骨脂总香豆素 | --22.5ug/kg51020 | 121212121211 | 17.11±8.948.53±5.65△14.04±6.68*12.65±6.7213.83±9.6715.57±10.13* | 120.07±48.5859.03±17.49△△△91.46±29.80**67.05±24.3586.80±31.28*121.20±39.64*** | 19.98±12.4411.12±4.71△20.18±11.92*12.93±5.5914.16±7.8119.40±5.95** |
组别 | 剂量mg/kg | 动物数(n) | 脾脏 | 肾脏 | 胸腺 | 肾上腺 | 子宫 |
正常组模型组阳性组补骨脂总香豆素 | --22.5ug/kg51020 | 151718171818 | 0.22±0.030.23±0.030.22±0.030.22±0.030.23±0.030.22±0.03 | 0.60±0.060.57±0.060.60±0.050.60±0.050.59±0.050.60±0.06 | 0.099±0.0150.099±0.0100.100±0.0160.104±0.0160.102±0.0160.103±0.016 | 0.031±0.0120.021±0.005△△0.041±0.019***0.035±0.015*0.041±0.016***0.038±0.014*** | 0.182±0.0540.104±0.046△△△0.156±0.049**0.132±0.031*0.137±0.034*0.147±0.041** |
组别 | 剂量mg/kg | 动物数(n) | 钙(%) | 磷(%) | 镁(%) | 锌mg/kg | 锰mg/kg | 铜mg/kg |
正常组模型组阳性组补骨脂总香豆素 | --22.5ug/kg102040 | 151718171618 | 4.48±0.184.37±0.12△4.51±0.24*4.53±.24*4.53±0.26*4.58±0.22*** | 11.34±0.2611.15±0.29△11.34±0.23*11.26±0.5211.60±0.29***11.59±0.36*** | 0.42±0.020.40±0.03△0.42±0.02*0.42±0.020.41±0.020.43±0.02* | 190.72±6.66192.04±5.0189.49±5.45196.05±9.39187.59±8.04187.09±6.57 | 5.55±0.435.27±0.415.50±0.555.69±0.805.45±1.225.63±0.90 | 3.38±0.433.25±0.233.33±0.303.41±0.323.11±0.243.36±0.35 |
组别 | 剂量mg/kg | 动物数(n) | TBV(%) | MTPT(μm) | Nocy(%) | CBV(%) | MOSW(μm) |
正常组模型组阳性组补骨脂总香豆素 | --22.5ug/kg51020 | 151718171618 | 56.27±8.1839.58±8.02△△△54.82±6.24***44.36±4.58*48.81±0.52**55.66±5.16*** | 104.00±8.0978.87±7.23△△△114.24±10.37***96.46±7.64***105.02±14.79***117.26±17.28*** | 6.27±1.4010.86±2.63△△△7.21±1.99***7.94±2.19*7.61±2.03**6.65±2.86*** | 89.30±0.2586.51±0.61△△△89.43±1.14***89.38±2.40**88.92±0.35**93.06±2.06*** | 49.35±10.9531.52±11.23△△△46.63±8.54***41.86±10.17***44.97±14.09***46.86±7.69*** |
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200610076304 CN101057885B (zh) | 2006-04-20 | 2006-04-20 | 一种治疗骨质疏松的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200610076304 CN101057885B (zh) | 2006-04-20 | 2006-04-20 | 一种治疗骨质疏松的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101057885A true CN101057885A (zh) | 2007-10-24 |
CN101057885B CN101057885B (zh) | 2012-12-12 |
Family
ID=38864288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200610076304 Active CN101057885B (zh) | 2006-04-20 | 2006-04-20 | 一种治疗骨质疏松的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101057885B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101244151B (zh) * | 2008-03-03 | 2010-10-13 | 刘廷剑 | 一种治疗痢疾的药物 |
CN102641328A (zh) * | 2012-05-17 | 2012-08-22 | 中南大学 | 一种补骨脂提取物及其制备和应用方法 |
CN104288219A (zh) * | 2014-10-14 | 2015-01-21 | 新乡医学院 | 补骨脂衍生物透皮吸收剂的制备方法和临床应用 |
CN106728679A (zh) * | 2016-12-30 | 2017-05-31 | 福建中医药大学 | 一种用于抗骨量丢失的分子中药缓释片及其制备方法 |
CN111840360A (zh) * | 2020-04-14 | 2020-10-30 | 江苏省中医药研究院 | 补骨脂总苷提取物的抗骨质疏松新用途 |
CN113559139A (zh) * | 2020-04-29 | 2021-10-29 | 周亚伟 | 一种葵花盘总香豆素提取物及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1446814A (zh) * | 2003-03-07 | 2003-10-08 | 上海大学 | 补骨脂素与异补骨脂素的制造方法 |
CN1543945A (zh) * | 2004-03-24 | 2004-11-10 | 吉林省中医中药研究院 | 从补骨脂中提取单体成分的工艺及其药物制剂 |
-
2006
- 2006-04-20 CN CN 200610076304 patent/CN101057885B/zh active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101244151B (zh) * | 2008-03-03 | 2010-10-13 | 刘廷剑 | 一种治疗痢疾的药物 |
CN102641328A (zh) * | 2012-05-17 | 2012-08-22 | 中南大学 | 一种补骨脂提取物及其制备和应用方法 |
CN104288219A (zh) * | 2014-10-14 | 2015-01-21 | 新乡医学院 | 补骨脂衍生物透皮吸收剂的制备方法和临床应用 |
CN106728679A (zh) * | 2016-12-30 | 2017-05-31 | 福建中医药大学 | 一种用于抗骨量丢失的分子中药缓释片及其制备方法 |
CN111840360A (zh) * | 2020-04-14 | 2020-10-30 | 江苏省中医药研究院 | 补骨脂总苷提取物的抗骨质疏松新用途 |
CN113559139A (zh) * | 2020-04-29 | 2021-10-29 | 周亚伟 | 一种葵花盘总香豆素提取物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN101057885B (zh) | 2012-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101057885A (zh) | 一种治疗骨质疏松的中药组合物及其制剂和用途 | |
CN1652807A (zh) | 用于治疗男性和女性性无能的制剂 | |
CN1876003A (zh) | 白首乌有效部位的制备方法及其在治疗失眠药物中的用途 | |
CN100344642C (zh) | 亚麻籽木脂素总糖苷提取物的制备方法及其应用 | |
CN110511261B (zh) | 生物利用度提高的精制熊胆粉及其制法 | |
CN1813782A (zh) | 一种银杏达莫组合物、含有该组合物的药物及其制备方法 | |
CN1245398C (zh) | 黄芩素的提取工艺、药用组合物及制剂制备工艺 | |
CN113521143A (zh) | 一种用于祛湿减重的脐部滴液及其制备方法 | |
CN1679706A (zh) | 一种由三七、红景天制成的治疗心脑血管疾病的药物制剂及其制备方法 | |
CN101496828A (zh) | 葫芦巴总皂苷提取物的用途 | |
CN110559303A (zh) | 降血脂预防治疗心脑血管病和动脉粥样硬化的精制熊胆粉 | |
CN1556101A (zh) | 汉黄芩素的提取工艺、药用组合物及制剂制备工艺 | |
CN1686469A (zh) | 一种治疗冠心病的药物制剂及其制备方法 | |
CN100344315C (zh) | 一种促进骨折愈合的药物组合物及其制备方法 | |
CN115645459A (zh) | 肉苁蓉提取物的制备方法、肉苁蓉提取物与应用 | |
CN1293901C (zh) | 一种抗疱疹病毒的中药制剂及制备方法 | |
CN1209116C (zh) | 木通皂苷d在制备防治骨病药物中的应用 | |
CN1544429A (zh) | 蜂胶黄酮提取物的制备方法、药物制剂及医药新用途 | |
CN1186351C (zh) | 黄花倒水莲总皂苷及其药物组合物与制备方法 | |
CN1099878C (zh) | 红曲及其乙酸乙酯提取物在制备药品或保健品食品中的应用 | |
CN1254267C (zh) | 一种治疗胃脘痛的药物及其制备方法 | |
CN1440790A (zh) | 苍术油在制备治疗骨质疏松症药物中的应用 | |
CN1201810C (zh) | 一种治疗阳痿的中药 | |
CN101028318A (zh) | 一种穿心莲缓释制剂及其制备方法 | |
CN1593503A (zh) | 香加皮强心作用有效提取物、制备方法及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIDA SHIJIA TECHNOLOGY DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: ZHOU YAWEI Effective date: 20150121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150121 Address after: 100084 No. 123 North Main Street, Haidian District, Beijing, Zhongguancun Patentee after: Beida Shijia Technology Development Co. Ltd. Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Patentee before: Zhou Yawei |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 102206, 20 floor, No. 6, life road, Beijing, Changping District, 3 Patentee after: Beida Shijia Technology Development Co. Ltd. Address before: 100084 No. 123 North Main Street, Haidian District, Beijing, Zhongguancun Patentee before: Beida Shijia Technology Development Co. Ltd. |